Just finished attending the International CoBrCa conference in Barcelona. MINDACT and MammaPrint were two of the hot topics at the conference.
You can read in full in The Oncology News here:
Read my interview with The Sydney Morning Herald here:
Dr Martine Piccart and her colleagues have today published in the New England Journal of Medicine their results of the landmark international prospective randomized Microarray In Node negative Disease May Avoid Chemotherapy (MINDACT) study. MINDACT assessed MammaPrint genomic testing of nearly 7,000 women with early breast cancer. In Australia, Associate Professor Guy Hingston says that this is the biggest news in breast cancer management in 2016!
Read the article in The New England Journal of Medicine here: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602253
One in two women are increasing their risk of breast cancer by skipping regular mammograms simply because they are too busy, according to alarming new research. Breast Screen NSW recently surveyed 1000 women aged 50-74 and found half missed their regular appointment, with most citing a “lack of time” as the reason despite 95 per cent agreeing the free screening could save their life. “Twelve women get diagnosed every day in NSW and 17 a week die of breast cancer, and many of these deaths don’t need to happen because screening can pick up a cancer as small as a grain of rice before it’s even able to be felt,” Cancer Institute of NSW deputy CEO Professor Sanchia Aranda said.
I consider breast cancer screening time well spent, particularly if it saves your life! Dr Guy Hingston.
Congratulations Lleyton for beating Juan Martin Del Potro to get into the 3rd Round of the US Tennis Open just now. Good Work!